You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201851 - 201860 of 205243 results
  1. Fiber Scanning Stimulated Raman Scattering (SRS) Endoscope

    SBC: INVENIO IMAGING INC            Topic: NCI

    DESCRIPTION (provided by applicant): Achieving maximal tumor removal with minimal collateral damage to healthy tissue is a challenge in tumor surgery, because there are no reliable visual cues to indicate completeness of resection. In contrast, on a microscopic level, the differences between tumor and non-infiltrated tissues are clear. However, traditional histopathologic techniques require that t ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Therapeutic Antibody Discovery from Pancreatic Cancer B Cell Repertoires

    SBC: Gigagen, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The Specific Aim of this SBIR Phase I project is to build a technology for discovery of monoclonal antibody (mAb) drug candidates for pancreatic cancer from rare primary B cells. Pancreatic cancer has proven resilient to drugs that target oncology's usual suspects , including proteins related to angiogenesis, proliferation, and metastasis (Mackenzie and McCollu ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting ether lipid biosynthesis for disease

    SBC: ECHELON BIOSCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Cancer is a significant health burden in the US and across the globe, representing the second leading cause of death in the US. Cancer cells have metabolic pathways that are altered significantly compared to normal cells. As a result, the pathways involved (lipid biosynthesis for example) are considered excellent targets for therapeutic intervention. The levels ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Inhibitors of lactic acid transporter MCT4

    SBC: VETTORE, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Most cancer cells are highly glycolytic, metabolizing glucose to lactic acid even when sufficient oxygen is available to perform oxidative metabolism, a phenomenon known as the Warburg effect. The Warburg effect has been shown to promote tumor growth, enable survival, and stimulate metastasis. In this project, we describe a strategy to directly antagonize the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Design of a Covalent Inhibitor for c-Myc-Dependent Cancers

    SBC: SUVALENT THERAPEUTICS INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The leading commercial goal of our company is to develop novel therapeutics to inhibit the human oncogene, c-Myc. C-Myc is a major human oncogene that is estimated to contribute to at least 70% of all human cancers, most of which are aggressive and respond poorly to current therapies. Despite more than 30 years of research, the development of drugs that inhibit ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. An Intraoperative Guidance Platform for Radio Frequency Ablation

    SBC: NE SCIENTIFIC LLC            Topic: NCI

    DESCRIPTION (provided by applicant): The objective of this proposed research program is to develop a platform for planning and guidance during Radio Frequency Ablation (RFA). RFA is a thermally mediated ablation technique, where an applicator carrying oneelectrode is inserted into tumors percutaneously (or via laparoscopy, or open surgical approaches). Radio Frequency (RF) energy is applied, denat ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Screening with D. melanogaster to Discover Inhibitors G12V Mutated kRAS

    SBC: TOSK, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Somatic kRAS mutations, termed oncogenic kRas, are found at a high rate in many cancers. For example, in colon cancer, the rate is 40%. Mutated KRAS allows the EGF system to bypass its natural controls and operate continuously, locked in a pro-growth mode (wild-type kRas, but not oncogenic KRAS, is self- inactivating). Consistent with this mechanism, the presen ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Protease Activity Assay for Melanoma Prognostics

    SBC: ZYMERA, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The objective of this Phase I project is the development of novel assays for gelatinase - i.e., matrix metalloprotease 2 and 9 - activity using a proprietary enhanced Fluorescence Resonance Energy Transfer (FRET) probewith a formulation that enables highly sensitive and specific measurements with a simple workflow and a 10 minute incubation time. The assay will ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Early Detection of Bladder Cancer Using a Waveguide Array Biosensor

    SBC: Physical Optics Corporation            Topic: NCI

    DESCRIPTION (provided by applicant): Bladder cancer (BC) represents a major health problem throughout the world. It is estimated that in the United States, 73,510 men and women were diagnosed with BC and 14,880 died of the disease in 2012. Often, early diagnosis of cancer enhances survival rates and enables optimal risk assessment. One major problem for the diagnosis of BC is the lack of distinct ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. VLR-CART Cancer Immunotherapy

    SBC: Novab, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The mission of Novab is to utilize the unique properties of lamprey generated Variable Lymphocyte Receptors (VLRs) to develop effective, complementary and/or superior therapeutics to those currently derived from mammalian monoclonal antibodies (mMAbs). In the current application, we seek to initiate and demonstrate proof of concept for one commercial project w ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government